share_log

Mangoceuticals | UPLOAD: Others

Mangoceuticals | UPLOAD: Others

Mangoceuticals | UPLOAD:其他
美股SEC公告 ·  04/30 13:03
Moomoo AI 已提取核心信息
Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.
Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.
美国上市公司Mangoceuticals公司收到美国证券交易所(SEC)的通知,称其于2024年4月23日提交的S-1表格注册申请不需要审核。SEC的信函发给了Mangoceuticals的首席执行官Jacob D.Cohen。信中提醒公司及管理层,不论SEC的审核过程如何,都要对信息披露的准确性和充分性负责。SEC还提到了规则460和461,涉及到加快注册程序的请求。如需进一步查询,SEC提供了工业应用和服务办公室公司财务部工作人员Juan Grana的联系信息。
美国上市公司Mangoceuticals公司收到美国证券交易所(SEC)的通知,称其于2024年4月23日提交的S-1表格注册申请不需要审核。SEC的信函发给了Mangoceuticals的首席执行官Jacob D.Cohen。信中提醒公司及管理层,不论SEC的审核过程如何,都要对信息披露的准确性和充分性负责。SEC还提到了规则460和461,涉及到加快注册程序的请求。如需进一步查询,SEC提供了工业应用和服务办公室公司财务部工作人员Juan Grana的联系信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息